Skip to content
Dr Zarir F. Udwadia
  • Home
  • About
    • Achievements
    • Publications
    • Highlights
    • News & Updates
  • Gallery
  • Patient Information
    • Asthma
    • COPD/Emphysema
    • Bronchiectasis
    • Interstitial Lung Disease
    • Idiopathic Pulmonary Fibrosis
    • Sarcoidosis
    • Tuberculosis
    • Multi-drug resistant tuberculosis
    • Obstructive Sleep Apnea Syndrome
  • Contact
  • Corona Updates
Menu

‘Universal’ access for MDR-TB limited without the involvement of the private sector.

Go to Publication

You Might Also Like

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.

August 30, 2019

Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India.

July 11, 2012

Spontaneous resolution of diffuse alveolar septal amyloidosis.

July 3, 2001

Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres

August 30, 2019

Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.

March 2, 2015

Hinduja Hospital,

Mahim, Mumbai – 400016

Appointment –
022 45108181, 022 67668181

Office – 022 24447353

Breach Candy Hospital,

B. Desai Road, Mumbai – 400026

Appointment – 5-8 pm
022 23667900
022 23667995

 

Thomas Cook Building,

DN Road, Mumbai – 400001

Appointment – After 6 pm
022 22046210
022 67439337

Copyright 2023 - Dr.Zarir Udwadia
Close Menu